## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.2% below STRENGTH zone (3.0-6.0%); PEG 1.49 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($71.14)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Henry Schein, Inc. (HSIC): A Bull Case Theory**
- Source: Finviz | 20251209T200814 | Bullish | Relevance: 99%
-  This article summarizes a bullish thesis for Henry Schein, Inc. (HSIC), highlighting its current undervaluation at 13x EPS despite being the largest dental distributor in the U.S. Key growth catalysts include the upcoming announcement of a new CEO, increased private-label penetration, cost optimization, and AI-driven growth through its dental software business. The company also benefits from an ongoing share repurchase program, suggesting a path to over $7 EPS within two to three years and offering a favorable risk/reward profile for investors.

**2. Gabelli Funds LLC Sells 16,750 Shares of Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251208T114922 | Neutral | Relevance: 99%
-  Gabelli Funds LLC reduced its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 4.8% during the second quarter, selling 16,750 shares. After the transaction, Gabelli Funds LLC owned 329,336 shares valued at approximately $24.06 million. Henry Schein reported strong quarterly earnings, beating analyst estimates, and has received an average "Hold" rating from Wall Street analysts with an average price target of $76.17.

**3. SVB Wealth LLC Invests $1.42 Million in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251209T142609 | Somewhat-Bullish | Relevance: 98%
-  SVB Wealth LLC acquired a new stake of 19,364 shares in Henry Schein, Inc. (NASDAQ:HSIC) during Q2, valued at approximately $1.42 million. Institutional investors now own about 96.62% of the company's stock, and analysts maintain an average "Hold" rating with a target price of $76.92. Henry Schein recently surpassed quarterly EPS estimates and provided FY2025 guidance.

**4. Henry Schein to renominate KKR designees to board for 2026 term**
- Source: Investing.com | 20251209T132633 | Bullish | Relevance: 98%
-  Henry Schein, Inc. announced its decision to renominate Max Lin and William K. Daniel, both KKR designees, to its board of directors for election at the company's 2026 annual meeting. This move follows KKR Hawaii Aggregator L.P.'s exercise of an extension election under a Strategic Partnership Agreement. The company also reported strong Q3 2025 earnings and an expanded distribution agreement with vVARDIS for Curodont Repair Fluoride Plus.

**5. HSIC Stock Benefits From Expanded Partnership With vVARDIS**
- Source: MSN | 20251207T150834 | Bullish | Relevance: 98%
- This article mentions that HSIC Stock is benefiting from an expanded partnership with vVARDIS. Without more content, further details on the nature or impact of this partnership are unavailable.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 0 ($0.00M) |
| Sells | 4 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +2.9% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.49 suggests fair value with growth premium. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.0B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 7.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.49 |
| Forward P/E | 14.1 |
| Current P/E | 15.2 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.7% to 0.2% (+2.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.8pp (needs >3.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Outperforming sector by 4.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.18% (CS: 60) | Neutral |
| RSI_14 | 60.9 | Neutral |
| MACD Histogram | -0.22 | Bearish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.088x | Above |
| vs SMA200 | 1.076x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $74.44
- **Stop Loss:** $71.14 (4.4% risk)
- **Target:** $77.74 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 90
- **Position Value:** $6,699.60
- **Portfolio %:** 6.70%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*